Table 3:
Baseline characteristics of the non-rheumatic and rheumatic AS patients who underwent TAVR, before and after PS weighting adjustment
| Variable | Before adjustment | After adjustment | Standardized differences | |||
|---|---|---|---|---|---|---|
| Non-rheumatic AS (N=88,554) | Rheumatic AS (N=605) | P value | Non-rheumatic AS (N=88,554) | Rheumatic AS (N=605) | ||
| Age | 81.2±8.1 | 79.4±8.1 | <0.001 | 79.41 (8.05) | 79.41 (8.85) | 0.0 |
| Race | ||||||
| White | 92.2% | 90.4% | 0.2 | 0.91 | 0.91 | 0.0 |
| Black | 4.0% | 4.3% | 0.04 | 0.04 | ||
| Male sex | 53.3% | 40.0% | <0.001 | 0.40 (0.49) | 0.40 (0.49) | 0.0 |
| Hypertension | 94.3% | 93.7% | 0.5 | 0.94 (0.24) | 0.94 (0.24) | 0.0 |
| Diabetes mellitus | 41.6% | 44.8% | 0.1 | 0.45 (0.50) | 0.45 (0.50) | 0.0 |
| Heart failure | 78.5% | 82.6% | 0.01 | 0.83 (0.38) | 0.83 (0.38) | 0.0 |
| Lung disease | 36.4% | 44.0% | <0.001 | 0.44 (0.50) | 0.44 (0.50) | 0.0 |
| Liver disease | 4.1% | 4.1% | 0.9 | 0.04 (0.20) | 0.04 (0.20) | 0.0 |
| Chronic kidney disease | 28.8% | 29.6% | 0.7 | 0.30 (0.46) | 0.30 (0.46) | 0.0 |
| End stage renal disease | 3.7% | 4.6% | 0.2 | 0.05 (0.21) | 0.05 (0.21) | 0.0 |
| Peripheral arterial disease | 33.3% | 32.9% | 0.9 | 0.33 (0.47) | 0.33 (0.47) | 0.0 |
| Prior ischemic stroke | 9.2% | 11.8% | 0.03 | 0.12 (0.32) | 0.12 (0.32) | 0.0 |
| Coronary artery disease | 47.2% | 56.4% | <0.001 | 0.56 (0.50) | 0.56 (0.50) | 0.0 |
| Prior revascularization | 19.9% | 21.0% | 0.5 | 0.21 (0.41) | 0.21 (0.41) | 0.0 |
| Atrial fibrillation | 42.0% | 53.0% | <0.001 | 0.53 (0.50) | 0.53 (0.50) | 0.0 |
| Depression | 15.1% | 19.5% | 0.003 | 0.19 (0.40) | 0.19 (0.40) | 0.0 |
| Hypothyroidism | 25.2% | 28.9% | 0.04 | 0.29 (0.45) | 0.29 (0.45) | 0.0 |
| Drug abuse | 0.9% | -- | 0.3 | 0.01 (0.11) | 0.01 (0.11) | 0.0 |
| Anemia | 38.7% | 50.9% | <0.001 | 0.51 (0.50) | 0.51 (0.50) | 0.0 |
| Connective tissue disease | 6.7% | 8.8% | 0.04 | 0.09 (0.28) | 0.09 (0.28) | 0.0 |
| Alcohol abuse | 2.4% | 3.5% | 0.09 | 0.03 (0.18) | 0.03 (0.18) | 0.0 |
| Lymphoma | 1.6% | 2.3% | 0.2 | 0.02 (0.15) | 0.02 (0.15) | 0.0 |
| Electrolytes abnormality | 40.6% | 57.9% | <0.001 | 0.58 (0.49) | 0.58 (0.49) | 0.0 |
| Obesity | 25.6% | 27.1% | 0.4 | 0.27 (0.44) | 0.27 (0.44) | 0.0 |
| Psychosis | 2.1% | 3.8% | 0.004 | 0.04 (0.19) | 0.04 (0.19) | 0.0 |
| Pulmonary hypertension | 7.4% | 11.2% | <0.001 | 0.11 (0.31) | 0.11 (0.31) | 0.0 |
| Tumor without metastasis | 4.9% | 5.1% | 0.8 | 0.05 (0.22) | 0.05 (0.22) | 0.0 |
| Metastatic disease | 1.2% | 2.0% | 0.08 | 0.02 (0.14) | 0.02 (0.14) | 0.0 |
| Peptic ulcer disease | 2.4% | 2.6% | 0.7 | 0.03 (0.16) | 0.03 (0.16) | 0.0 |
| Weight loss | 7.9% | 12.6% | <0.001 | 0.12 (0.33) | 0.12 (0.33) | 0.0 |
| Prior bleeding | 18.5% | 26.5% | <0.001 | 0.26 (0.44) | 0.26 (0.44) | 0.0 |
| Prior cerebral bleeding | 0.5% | -- | 0.002 | 0.01 (0.12) | 0.01 (0.12) | 0.0 |
| Prior gastrointestinal bleed | 10.3% | 16.2% | <0.001 | 0.16 (0.37) | 0.16 (0.37) | 0.0 |
| Prior defibrillator | 2.6% | 3.5% | 0.2 | 0.03 (0.18) | 0.03 (0.18) | 0.0 |
| Prior pacemaker | 8.0% | 10.9% | 0.008 | 0.11 (0.31) | 0.11 (0.31) | 0.0 |
| Prior sleep apnea | 11.9% | 14.7% | 0.04 | 0.15 (0.35) | 0.15 (0.35) | 0.0 |
| Smoking | 15.1% | 20.0% | <0.001 | 0.20 (0.40) | 0.20 (0.40) | 0.0 |
| Frailty score median (IQR) | 6.9 (3.0–13.1) | 11.3 (4.9–19.6) | <0.001 | 13.4 (10.7) | 13.43(10.7) | 0.0 |
| High frailty | 19.7% | 39.0% | <0.001 | 0.39 (0.49) | 0.39 (0.49) | 0.0 |
Values are presented as percentages, mean (SD) or median (IQR)
Cells with N<11 were suppressed with (--)per CMS policy.